GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Jinyu Bio-Technology Co 600201.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

12.28

-1.52%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Jinyu Bio-Technology Co

Its shares trade on Shanghai under the ticker 600201.SS. It has been listed since 15 January 1999. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.40bn and net income of CN¥100.1m. At that date it held total assets of CN¥6.61bn and shareholders' equity of CN¥5.37bn.

Jinyu Bio-Technology Co., Ltd. engages in the research and development, production, and sale of veterinary biological products. The company is headquartered in Hohhot, Neimenggu. The firm mainly provides veterinary vaccines. The firm is also engaged in textile processing business, and the provision of property leasing and management activities. The firm also provides energy products.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
15 Jan 1999
Employees
1,618

Leadership

Pay as last reported

  • Mr. Chongyu ZhangChairman of the Board, since 1993CN¥1.6m
  • Ms. Jing ZhangPresident, Vice Chairman of the Board, since 2016CN¥1.4m
  • Mr. Min PengChief Financial Officer, Secretary of the Board, Director, since 2022CN¥1.6m
  • Mr. Rong LiVice PresidentCN¥660,000
  • Mr. Riming GaoDirectorCN¥1.4m
  • Ms. Ming GengIndependent Director
  • Ms. Chang'e ShenIndependent DirectorCN¥136,800
  • Mr. Zhenping WuIndependent DirectorCN¥75,500
  • Ms. Guihong ZhangIndependent DirectorCN¥136,800

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
63
Environment
68
Social
61
Governance
62
Carbon reduction policy
Yes
Human rights policy
Yes

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Hohhot, Neimenggu with 1,618 employees
  • Engages in R&D, production, and sale of veterinary biological products
  • Provides veterinary vaccines as a main product

Weaknesses

  • Also engaged in textile processing business
  • Provides property leasing and management activities
  • Offers energy products as part of business

Opportunities

  • Potential growth in veterinary biological products market
  • Expansion of R&D capabilities for new products
  • Increased demand for veterinary vaccines

Threats

  • Diversification into non-core businesses like textiles
  • Competition in veterinary biological products sector
  • Regulatory challenges in multiple business areas

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.